GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » Accounts Receivable

Kiadis Pharma NV (XAMS:KDS) Accounts Receivable : €0.00 Mil (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Kiadis Pharma NV's accounts receivables for the quarter that ended in Dec. 2020 was €0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Kiadis Pharma NV's Days Sales Outstanding for the quarter that ended in Dec. 2020 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Kiadis Pharma NV's Net-Net Working Capital per share for the quarter that ended in Dec. 2020 was €-2.03.


Kiadis Pharma NV Accounts Receivable Historical Data

The historical data trend for Kiadis Pharma NV's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Accounts Receivable Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kiadis Pharma NV Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Kiadis Pharma NV Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Kiadis Pharma NV's Days Sales Outstanding for the quarter that ended in Dec. 2020 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/17.5*91
=0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Kiadis Pharma NV's accounts receivable are only considered to be worth 75% of book value:

Kiadis Pharma NV's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2020 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(13.658+0.75 * 0+0.5 * 0-95.681
-0-0)/40.3085
=-2.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Kiadis Pharma NV Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (XAMS:KDS) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines